JACC: Cardiovascular Imaging
Volume 5, Issue 2 , Pages 131-140, February 2012

Echocardiography, Natriuretic Peptides, and Risk for Incident Heart Failure in Older Adults:

The Cardiovascular Health Study

  • Andreas P. Kalogeropoulos, MD

      Affiliations

    • Emory Clinical Cardiovascular Research Institute, Emory University, Atlanta, Georgia
  • ,
  • Vasiliki V. Georgiopoulou, MD

      Affiliations

    • Emory Clinical Cardiovascular Research Institute, Emory University, Atlanta, Georgia
  • ,
  • Christopher R. deFilippi, MD

      Affiliations

    • Maryland Heart Center, University of Maryland, Baltimore, Maryland
  • ,
  • John S. Gottdiener, MD

      Affiliations

    • Maryland Heart Center, University of Maryland, Baltimore, Maryland
  • ,
  • Javed Butler, MD, MPH

      Affiliations

    • Emory Clinical Cardiovascular Research Institute, Emory University, Atlanta, Georgia
    • Corresponding Author InformationReprint requests and correspondence: Dr. Javed Butler, Emory Clinical Cardiovascular Research Institute, 1462 Clifton Road NE, Suite 504, Atlanta, Georgia 30322
  • ,
  • Cardiovascular Health Study

Received 11 July 2011; received in revised form 20 October 2011; accepted 17 November 2011.

Objectives

This study sought to examine the potential utility of echocardiography and N-terminal pro–B-type natriuretic peptide (NT-proBNP) for heart failure (HF) risk stratification in concert with a validated clinical HF risk score in older adults.

Background

Without clinical guidance, echocardiography and natriuretic peptides have suboptimal test characteristics for population-wide HF risk stratification. However, the value of these tests has not been examined in concert with a clinical HF risk score.

Methods

We evaluated the improvement in 5-year HF risk prediction offered by adding an echocardiographic score and/or NT-proBNP levels to the clinical Health Aging and Body Composition (ABC) HF risk score (base model) in 3,752 participants of the CHS (Cardiovascular Health Study) (age 72.6 ± 5.4 years; 40.8% men; 86.5% white). The echocardiographic score was derived as the weighted sum of independent echocardiographic predictors of HF. We assessed changes in Bayesian information criterion (BIC), C index, integrated discrimination improvement (IDI), and net reclassification improvement (NRI). We examined also the weighted NRI across baseline HF risk categories under multiple scenarios of event versus nonevent weighting.

Results

Reduced left ventricular ejection fraction, abnormal E/A ratio, enlarged left atrium, and increased left ventricular mass were independent echocardiographic predictors of HF. Adding the echocardiographic score and NT-proBNP levels to the clinical model improved BIC (echocardiography: −43, NT-proBNP: −64.1, combined: −68.9; all p < 0.001) and C index (baseline: 0.746; echocardiography: +0.031, NT-proBNP: +0.027, combined: +0.043; all p < 0.01), and yielded robust IDI (echocardiography: 43.3%, NT-proBNP: 42.2%, combined: 61.7%; all p < 0.001), and NRI (based on Health ABC HF risk groups; echocardiography: 11.3%; NT-proBNP: 10.6%, combined: 16.3%; all p < 0.01). Participants at intermediate risk by the clinical model (5% to 20% 5-yr HF risk; 35.7% of the cohort) derived the most reclassification benefit. Echocardiography yielded modest reclassification when used sequentially after NT-proBNP.

Conclusions

In older adults, echocardiography and NT-proBNP offer significant HF risk reclassification over a clinical prediction model, especially for intermediate-risk individuals.

Key Words:  epidemiology , heart failure , risk prediction , risk score , risk stratification

Abbreviations and Acronyms:  BIC, Bayesian information criterion, EF, ejection fraction, HF, heart failure, IDI, integrated discrimination improvement, LV, left ventricular, LVEF, left ventricular ejection fraction, NRI, net reclassification improvement, NT-proBNP, N-terminal pro–B-type natriuretic peptide

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The research reported in this paper was supported by contract numbers N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number HL080295 from the National Heart, Lung, and Blood Institute (NHLBI) and grant number AG-023269 from the National Institute on Aging (NIA), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through AG-15928, AG-20098, and AG-027058 from the NIA, HL-075366 from NHLBI, and the University of Pittsburgh Claude D. Pepper Older Americans Independence Center P30-AG-024827. This project was also partially funded by an Emory University Heart and Vascular Board grant entitled “Novel Risk Markers and Prognosis Determination in Heart Failure” and Public Health Service Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources. All authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PII: S1936-878X(11)00890-4

doi:10.1016/j.jcmg.2011.11.011

JACC: Cardiovascular Imaging
Volume 5, Issue 2 , Pages 131-140, February 2012